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Abstract
Sponsored by the New York Academy of Sciences and with support from the National Institute of
Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation,
“Advancing Drug Discovery for Schizophrenia” was held March 9–11 at the New York Academy
of Sciences in New York City. The meeting, comprising individual talks and panel discussions,
highlighted basic, clinical, and translational research approaches, all of which contribute to the
overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This
report surveys work by the vanguard of schizophrenia research in such topics as genetic and
epigenetic approaches; small molecule therapeutics; and the relationships between target genes,
neuronal function, and symptoms of schizophrenia.
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schizophrenia; genetics; GWAS; neuronal function; small molecules; therapeutics
Background and perspectives: keynote lectures
Session chairs: Stephen R. Marder and Bryan Roth
Though pioneering pharmacotherapy for the treatment of schizophrenia occurred in the
1950s with the introduction of antipsychotics, there have been decidedly few major
innovations in the intervening years. Indeed, the current classes of drugs available largely
involve the same mechanisms of action and the same neurobiological targets. Compounding
the lack of progress has been the systemic pull-back of the pharmaceutical industry from
research and development of new treatments for schizophrenia.
With the advent of successful methods for identifying anomalies at the genetic level,
schizophrenia and other neuropsychiatric disorders stand to benefit immensely from
incorporating these approaches and broadening our understanding of the pathogenesis of
these illnesses.
“Advancing Drug Discovery for Schizophrenia” convened with an opening session of
keynote lectures moderated by session chairs Stephen R. Marder (University of California,
Los Angeles) and Bryan Roth (University of North Carolina School of Medicine). Marder
called for a change in the way schizophrenia treatment has previously been conceptualized
by moving away from focusing only on treating symptoms in individuals who are in the
acute phase of the illness. Innovative drugs may emerge from improving our understanding
of the pathologic processes that occur early in the development of the illness, thus providing
strategies for altering the course of the disorder. Importantly, genetic and epigenetic
approaches present a very promising means by which to accomplish this goal.
Genetic and epigenetic approaches to studying schizophrenia
Patrick F. Sullivan (University of North Carolina at Chapel Hill) introduced the advantages
of genetic approaches to schizophrenia by listing several benefits: the temporality of
exposure to genetic risk factor preceding disease can be reasonably assumed; attempts at
unbiased searches are possible; and, in the past two years, there has been substantial
progress in uncovering the genetic basis of schizophrenia. He suggested that the purpose of
employing genetic techniques is to look both for genetic variance that confers risk or
prevention and for whether multiple genes work in concert to form pathways to an illness.
To illustrate this point, he offered the analogy of a match to a forest fire—genetic studies
seek to identify the initiating event in a disorder, or in other words, the “match” that sparks
the fire.
This line of work has begun to make progress.1,2 Sullivan noted that there are novel and
robust findings that include common variation in the major histocompatibility complex, the
region encoding the microRNA miR-137, and four predicted targets of miR-137. Copy
number variants that are rare but have high penetrance with robust results include regions on
1q21.1, 15q13.3, 16p11.2, 22q11.2, and NRX1. At this point, up to 15 possible genetic loci
for schizophrenia have been identified. Further, Sullivan stressed that the accumulated data
suggest that schizophrenia is relatively highly polygenic, which may be a general feature of
complex traits. For example, various genes may actually code at the symptom level versus
the disorder level (Table 1).
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The results to date are notable, Sullivan underscored, in that the novelty of findings
correspond relatively poorly to prior ideas about the etiology of schizophrenia. Empirical
data suggest that both common and rare variations are involved in the etiology of
schizophrenia. Rare variant–only models have been evaluated and are not consistent with the
data. Sullivan suggested that with genome-wide association studies (GWAS), we can,
however, estimate that increasing sample sizes are likely to produce more significant loci
and considerably better pathway analyses. He likened GWAS to a powerful centrifuge that
allows for the separation of specific genes. Most heartening, he suggested, is the likelihood
that the discovery profile for schizophrenia has a linear trajectory—increasingly larger
samples will lead to an increasing number of loci identified.
Genetic architecture of psychotic illness
Edward M. Scolnick (Broad Institute of MIT and Harvard University) began by suggesting
the great importance of unraveling the full genetic architecture of schizophrenia and bipolar
disorder as the critical step in establishing their underlying neurobiology. While the
overarching theme of the conference pointed to a general stagnation in the field of
schizophrenia treatment, Scolnick lauded the significant strides made recently. In other
words, the field has become “unstuck.” This movement could also be attributed to the
application of three new technologies: human genetics, optogenetic methods to manipulate
specific circuits in the brain, and induced pluripotent stem cells.
Scolnick noted the apparent disparity between developments in schizophrenia versus cancer
treatments. Bolstering this swell in cancer drug development is the increased understanding
of the genetic and molecular aspects of various forms of cancer, something that, given the
limited knowledge of its genetic basis, is not yet possible for schizophrenia.
In the past three years, however, using detailed maps of the human genome and doing
association studies, a number of risk genes for schizophrenia and bipolar illness have been
identified. CNVs (copy number variants) and genomic associations have been identified
with a high degree of statistical certainty; some of the CNVs are de novo and some are
inherited. Scolnick referred to characterizing diseases by the frequency of variants in
addition to penetrance. For example, Mendelian diseases possess high penetrance and are
deterministic of the development of the disease. However, many diseases posses a mixture
of high- and low-frequency variation, indicated Scolnick. Increasingly, GWAS methodology
is being used to investigate the penetrance of diseases and is appropriate for application to
schizophrenia. Pathways involving synaptic proteins, the WNT signaling pathway, as well
as miR-137 have been identified, which now provide clues about the biology of some
illnesses. In addition, it has become clear that schizophrenia and autism may share some risk
genes in common. Though the outcomes are very different, it may be possible, Scolnick
suggested, that causative DNA variants may someday be used diagnostically.
Scolnick concluded by posing the idea that the full-scale application of genomics is now
limited only by money and time to unravel the full genetic architecture of these illnesses.
Further, given the burden of these illnesses, he reasoned that there is “no excuse” for NIH
and NIMH funds not to be made available to perform the needed genetic studies and to
finally enlighten their etiologies. He continued by saying that until we understand fully the
genes that cause these illnesses the field will remain a “backwater of medicine.” Funding for
neuroscience is certainly needed to understand their pathophysiology, but without an
understanding of the genetic bases, he cautioned, scientists will continue to guess at what to
work on to elucidate the illness and discover new targets for treatment.
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What can we learn from animal models of schizophrenia?
Applying genetic methodologies to psychiatric disorders presents unique challenges,
suggested Eric J. Nestler (Mount Sinai Medical Center). These include that they are
categorically defined by behavioral abnormalities and that the genetic risks involved are
likely to be a combination of multiple genetic variations. Thus, progress in understanding
the etiology and pathophysiology of schizophrenia has been frustratingly slow, as has been
the discovery of significant, novel therapeutic mechanisms. The exceedingly challenging
neurobiology of higher brain function and the ethical and practical difficulties of examining
the living human brain have no doubt contributed to this relatively slow progress. Another
important factor is the extremely challenging nature of modeling schizophrenia in laboratory
animals.3 This is due to the inaccessibility, in animals, of many of the key symptoms of
schizophrenia, the subjective nature of the symptoms, the lack of objective biomarkers, and
the early state of knowledge of the underlying genetics and neurobiology of the syndrome.
What we have learned from genetic studies of schizophrenia thus far, Nestler argued, is
especially complicating vis-à-vis animal models, because most genes of relatively strong
effect implicated in schizophrenia are also implicated in bipolar disorder and even autism.
Moreover, Nestler proposed that what can be learned from placing genes of very small effect
into laboratory animals is itself questionable. Indeed, Nestler continued by saying that most
available animal models of schizophrenia have significant limitations, ranging from weak
validation to poor predictive power for drug efficacy in humans.
Illustrating the complications that arise from translating models of human disorders in, for
example, murine models, Nestler explored difficulties for establishing construct validity. For
example, though genes may be associated with schizophrenia, abnormalities in these specific
genes may cause schizophrenia but may also cause other disorders. Moreover, there is
difficulty in making animal models as complicated as human models, and this too may
require experimentally manipulating multiple genes.
Nestler also discussed two other forms of validity in respect to the limitations of animal
models. Perhaps the most obvious limitation is the lack of face validity—there are simply
features of psychiatric disorders that are not accessible in animals. Second, Nestler
referenced the lack of predictive validity of animal models. Not only are there no new
medications to test for efficacy in animals, but we must also interpret any response to drugs
with great caution. In contrast, there may be better face validity for some of the negative
symptoms associated with schizophrenia (e.g., social withdrawal and anhedonia), which
have been modeled successfully, but may not be unique to this illness.
Concluding his talk, Nestler remained optimistic that, with time, the genes that confer risk or
resilience in mental illness will be determined, citing advances in autism as support. The
generation of convincing and useful animal models of schizophrenia thus represents a major
set of challenges that will not have easy answers. On the other hand, given current
limitations of clinical studies, Nestler concluded that it is hard to imagine significant
progress in schizophrenia pathophysiology or therapeutics without good animal models.
Session II: Genetic and epigenetic approaches
Session chair: Mark A. Geyer
A novel therapeutic target for psychosis
The discovery of genes associated with risk for schizophrenia holds promise for identifying
therapeutic targets based on etiopathogenesis. Daniel R. Weinberger (National Institute of
Mental Health) reported recent work from his lab documenting an association with
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schizophrenia to the hERG family potassium channel gene, KCNH2.4 Risk-associated
variants predict expression of a novel brain and primate specific isoform, KCNH2 3.1,
which both has unique physiological properties and is upregulated in schizophrenia
prefrontal and hippocampal cortices. Because many antipsychotic drugs bind to KCNH2
channels, accounting in some cases for QT prolongation, and atypical agents such as
clozapine are particularly potent KCNH2 inhibitors, Weinberger and coworkers
hypothesized that activity at KCNH2 channels may be a therapeutic mechanism of
antipsychotic drugs. As a result, targeting the 3.1 isoform not expressed in the heart would
have a particularly favorable therapeutic-to-toxic ratio. Weinberger stated, “We have tested
the first hypothesis in two independent samples of patients who underwent placebo
controlled studies of antipsychotic therapy, including an inpatient sample from the CBDB/
NIMH experimental therapeutics unit (n = 59) and Caucasian subjects treated with
olanzapine as part of the CATIE trial from whom we also had drug clearance data (total N =
89).” In both groups, Weinberger and colleagues found that the KCNH2 genotype predicted
response to treatment (e.g., positive symptoms P < 0.0007, thought disturbance P < 0.0004
in the CBDB sample, positive symptoms P < 0.04 in CATIE). Currently, Weinberger’s
group is testing the second hypothesis in human and model cell lines that over-express
KNCH2 3.1 and also in a mouse model that overexpresses KCNH2 3.1 in cortex and shows
predicted abnormalities in K+ channel kinetics and in working memory.
Linking DNA structural variation to brain dysfunction and schizophrenia
Structural variation in the genome in the form of copy-number variants (CNVs;
submicroscopic gains or losses of segments of DNA) has now been identified as a major
contributing genetic factor in schizophrenia.
Maria Karayiorgou (Columbia University) discussed the importance of examining low-
frequency alleles with moderate effects, as they are easier to characterize and potentially
more likely to contribute to the development of the disorder. Further, exploring the genetic
variation in the landscape de novo may have great utility in delineating sporadic versus
inherited types of schizophrenia. Importantly, Karayiorgou suggested that inherited CNVs
are more disrupting than those that are de novo.
Karayiorgou focused on one such CNV on chromosome 22q11.2. Recent studies are
beginning to paint a clearer and more consistent picture of the impairments in psychological
and cognitive competencies that are associated with microdeletions in chromosome 22q11.2.
In contrast to previous talks stressing the uncertainty of associating schizophrenia risk with
any specific gene or CNV, Karayiourgou maintained that 30% of individuals with a deletion
on 22q11 develop schizophrenia or schizoaffective disorder. Indeed, parallel studies in
humans and animal models have begun to uncover the complex genetic and neural substrates
altered by this microdeletlon. For example, Krayiorgou illustrated studies that have begun to
identify CNVs that may explicate some of the working memory-related processing deficits
seen in schizophrenia, because they occur in regions that oversee microRNA, thus affecting
prefrontal cortex neuronal synaptic transmission and plasticity. In addition to offering a
deeper understanding of the effects of this genetic lesion, Krayiorgou ended her presentation
with the hope that these findings may guide analysis of other CNVs associated with
psychiatric disorders.
Targeting the neuro-epigenome in the prevention and treatment of psychosis
Alessandro Guidotti (University of Illinois at Chicago) began by stating that the efficacy of
current drugs is limited and that, without new developments, there is little hope for progress
in the treatment of schizophrenia. An area of research that holds promise is exploring the
role of the fundamental interaction between GABAergic interneurons and pyramidal
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neurons and how this function is compromised in schizophrenia and bipolar disorders.
Schizophrenia and bipolar disorder patients show a downregulation of GAD67, reelin, and
other genes expressed in telencephalic GABAergic neurons, likely associated with promoter
hypermethylation mediated by an overexpression of DNA methyltransferase (DNMT).5 The
inhibitory action of DNMT on gene expression may also occur through formation of
chromatin repressor complexes that include histone deacetylases (HDAC) or histone
methyltransferases, thereby shifting chromatin from a conformation permissive for
transcription to one that is repressive. Guidotti has concentrated on a pharmacological
strategy to reduce the hypermethylation of GABAergic promoters and to induce a
permissive chromatin conformation. This strategy is to administer drugs such as the HDAC
inhibitor valproate (VPA), which induces DNA demethylation when administered at doses
that facilitate chromatin remodeling.6
Studies employing this strategy in mice, as presented by Guidotti, suggest that when
combined with VPA, clinically relevant doses of clozapine elicit a synergistic potentiation of
VPA-induced GABAergic promoter demethylation (Fig. 1). Olanzapine and quetiapine (two
similar atypical antipsychotic drugs) also facilitate chromatin remodeling, but at doses
higher than used clinically, whereas haloperidol and risperidone are inactive. Hence,
Guidotti suggested the synergistic potentiation of VPA’s action on chromatin remodeling by
clozapine appears to be a unique property of the dibenzepines and is independent of their
action on catecholamine or serotonin receptors. Furthermore, the administration of clozapine
in conjunction with VPA reverses the downregulation of the GAD67 expression induced in
mice by seven days of methionine administration.5
Guidotti concluded by positing that chromatin remodeling mechanisms may be altered in the
brains of schizophrenia and bipolar disorder patients. Thus, by activating DNA
demethylation, the association of clozapine or its derivatives with VPA or other more potent
and selective HDAC inhibitors could be considered a promising prevention and treatment
strategy to normalize the GABAergic promoter hypermethylation and GABAergic gene
expression downregulation detected in the postmortem brain of schizophrenia and bipolar
patients.
Advanced paternal age alters complex behaviors and brain DNA methylation in offspring
Prompted by epidemiological research that shows advanced paternal age increases risk for
schizophrenia in offspring,a Jay Gingrich (Columbia University Medical School) discussed
potential epigenetic mechanisms behind this effect. With each round of sperm production,
epigenetic marks are erased and then reprogrammed—a process that may become degraded
with advanced paternal age. To explore this, Gingrich and colleagues compared the
offspring from older mouse fathers to those from young mouse fathers. Several behaviors
differed between the two, including measures of an open-field ambulatory test, startle
responses, and paired pulse inhibition. These mice showed distinct methylation patterns on
their genomes at 0.4 % of the methylation sites. At these sites, the offspring of older males
were less methylated than those of the younger males in introns, exons, and promoters.
These findings suggest that differences inboth the promoter activity and alternative splicing
patterns may drive some of the changes observed in the mice. Notably, hotspots of altered
DNA methylation could be found in schizophrenia-related genes, though, Gingrich noted,
the researchers didn’t select the mice for disease-related behaviors.
aSee the SRF hypothesis: http://www.schizophreniaforum.org/for/curr/Malaspina/default.asp
Marder et al. Page 6













Neuronal epigenome mapping in developing and diseased prefrontal cortex
Alterations in chromatin structure and function, including changes in levels or distribution of
histone lysine methylation markings and other epigenetic regulators of gene expression,
could affect neuronal signaling in schizophrenia and other major psychiatric disease.8
However, to date, relatively nothing is known about the regulation of neuronal and other cell
type–specific epigenomes in the diseased brain. Schahram Akbarian (University of
Massachusetts) opened his talk by pointing out the potential for neuroepigenome mapping
approaches to advancing the epigenetic field through focusing on the postmortem human
brain. Specifically, he discussed work exploring the genome-wide distribution of
trimethylated histone H3K4 (H3K4me3), an epigenetic histone mark associated with actual
or potential transcription, in neuronal nuclei collected postmortem from prefrontal cortex
(PFC) across a wide age range (0.5–70 years).
Neuronal nuclei from postmortem prefrontal cortex were immunotagged with NeuN
antibody, NeuN+ and NeuN− nuclei were sorted separately via fluorescence-activated “cell”
(nuclei) sorting (FACS), and purified mononuclesomes were enriched for H3K4me3
analyzed by massively parallel sequencing using an Illumina Solexa platform.9 Akbarian’s
group has identified 16,000–22,000 H3K4me3-enriched regions (peaks), the majority
located proximal to (within 2 kb of) the transcription start sites (TSS) of annotated genes.
These included signatures specific to neurons as well as signatures specific to individual
subjects (Fig. 2). Preliminary analyses presented by Akbarian provided evidence for a large-
scale remodeling of histone methylation landscapes in immature PFC neurons during early
infancy, with comparatively minor changes during subsequent periods of maturation and
aging. Further, he predicted that epigenome mapping in defined cell populations of the
diseased human brain, in conjunction with RNA and transcriptome profilings, could reveal
important information about gene expression alterations at specific loci. These approaches,
he stressed, will also be important to unravel the genetic and epigenetic risk architectures of
specific cases and, furthermore, reveal insight about developmental regulation of chromatin
structures in specific cell populations.
Session III: New molecular targets and approaches to small molecule
therapeutics
Session chair: Robert W. Buchanan
Development of novel antipsychotic drugs: new approaches to old problems
Dopamine D2 receptor antagonism is a unifying property of all antipsychotic drugs in use
for schizophrenia. Jeffrey A. Lieberman (Columbia University and New York State
Psychiatric Institute) stressed during his talk that, as a result, while these drugs can be
effective at ameliorating psychosis, they are largely ineffective at treating negative and
cognitive symptoms, can produce serious side effects involving different organ systems, and
may even contribute to gray matter volume reduction. The differences between the majority
of the current drugs, Lieberman suggested, are primarily due to side-effect profiles, with
pronounced side-effects often outweighing the therapeutic potential; additionally,
considerable heterogeneity in response to treatment exists.
For years, psychiatric researchers and pharmaceutical companies have sought to develop
mechanistically novel antipsychotic drugs based on targets other than dopamine receptors.
For example, Lieberman highlighted the considerable amount of work that has been devoted
to precedented targets and mechanisms (D-2, D-3 dopamine, and 5-HT2A serotonin
antagonism); novel mechanisms (partial agonism, functional selectivity); and novel targets
(glutamatergic, cholinergic, GABAergic), including intracellular signaling mechanisms
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(AKT, GSK). Unfortunately, drugs targeting many of these mechanisms were abandoned
before they were tested in clinical trials.
In addition, Lieberman offered the observation that increasing attention is being focused on
the complex genetics of schizophrenia as well as the signaling pathways implicated in its
pathophysiology. Lieberman’s presentation reviewed the limitations of existing therapeutic
agents and development strategies, including several of the major genetic findings that have
identified signaling pathways representing potential targets for novel pharmacological
intervention—for example, genes in the 22qll locus, DISC1, Neuregulin1/ ErbB4, and
components of the Akt/GSK-3 pathway.
Lieberman concluded that it may be critical both to consider the necessity of multiple
medications that treat different aspects (or domains) of schizophrenia and to renew
commitment to research and development of pharmacotherapy for the illness.
Allosteric modulators of metobotropic glutamate receptor 5 for the treatment of
schizophrenia
P. Jeffrey Conn (Vanderbilt University) presented work demonstrating the path between
hypotheses and actual treatments of schizophrenia. The glutamate/NMDA receptor function
hypofunction hypothesis has garnered wide attention because of its significant potential in
targeting the range of symptoms presented in schizophrenia, including positive, negative,
and cognitive symptoms. Further supporting this hypothesis, a large number of cellular and
behavioral studies suggest that selective agonists of the metabotropic glutamate receptors
(mGluRS) could provide a novel approach to treatment of schizophrenia.10 Unfortunately, it
has been difficult to develop compounds that act as selective orthosteric agonists of mGluRS
and that have properties likely to be suitable for development of therapeutic agents. Conn
presented work from his group, which has been successful in implementing a novel
approach to activation of these receptors by developing highly selective allosteric
potentiators of mGluR5.These compounds do not activatemGluR5 directly, but rather
potentiate the response of these receptors to the endogenous agonist. Thus, these allosteric
potentiators offer high selectivity for the targeted receptor and provide an exciting new
approach to development of novel selective activators of mGluR5 and other G protein–
coupled receptor (GPCR) subtypes.10
In vivo studies reveal that these compounds have robust effects in animal models, which
have been used to predict efficacy of novel antipsychotic agents. Conn showed findings that
demonstrate that introduction of these compounds reduces amphetamine-induced motor
hyperactivity, a putative animal model of limbic hyperactivity and positive symptoms of
schizophrenia. In addition, mGluR5-positive allosteric modulators (PAMs) enhance multiple
forms of synaptic plasticity in the central nervous system (CNS) and have cognition-
enhancing effects in animal models.11 These studies, therefore, provide an exciting new
approach for discovery of novel, highly selective activators of specific GPCR subtypes for
treatment of schizophrenia and other CNS disorders. In conclusion, Conn suggested that
recent advances in the discovery of a broad range of mGluR5 allosteric modulators with
different functional profiles will allow the development of a more complete understanding
of the properties of individual mGluR5-PAMs with the hope of determining which may be
most suitable for development as novel therapeutic agents.
Chemical genomic studies of DISC1/GSK3–mediated signaling in neuropsychiatric
disorders
A critical need exists for gaining insight into the underlying etiology and pathophysiology of
schizophrenia and other neuropsychiatric disorders in order to advance the development of
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new types of targeted therapeutic interventions. Surveying recent work, Stephen J. Haggarty
(Harvard Medical School, Broad Institute of MIT and Harvard University) presented studies
of the Disrupted in Schizophrenia 1 (DISC1) gene, which is disrupted by a balanced
chromosomal translocation t(1;11)(q42.1;q14.3) in a single extended Scottish family with a
high incidence of schizophrenia, major depression, and bipolar disorder. Studies have
revealed a key role for DISC1-mediated signaling in diverse aspects of neuroplasticity. One
of the direct binding targets of DISC1 is the multifunctional serine/threonine kinase GSK3,
which is known to play a key role in the regulation of neurogenesis and synaptic function.12
GSK3 has also been shown to be inhibited in vivo directly, and indirectly, by the mood
stabilizer lithium and indirectly through the activity of antipsychotics at various GPCRs.13
On the basis of these findings, as well as emerging human genetic studies implicating other
components of the GSK3 signaling pathway in the etiology of schizophrenia, Haggarty
discussed the advent of chemical genomic approaches to identify small molecule probes that
target known and novel components of DISC1/GSK3 signaling.
Using pharmacological and viral-mediated gene expression to modulate AKT kinase
activity, Haggarty presented work demonstrating a key role for AKT kinase activity in
determining the cellular and mood-related behavioral effects of lithium.13,14 In contrast,
selective and direct GSK3 inhibition by an ATP-competitive, highly selective, brain
penetrant GSK3 inhibitor (CHIR-99021) was found to bypass the requirement for AKT
activation (Fig. 3).14 In order to try to develop pathway-selective inhibitors of GSK3 and to
develop small molecule probes that enable the selective targeting of individual DISC1
domains, Haggarty’s group has used small molecule microarray screening to measure the
interaction of DlSC1 variants in a high throughput manner.
Finally, Haggarty presented efforts to use induced pluripotent stem cell (iPSC)–derived
human neurons for use in high-throughput screening for small molecule probes of DISC1/
GSK3 signaling. Haggarty showed findings that demonstrated the ability to identify known
and novel small molecules that regulate TCF/LEF–dependent transcription that is under
control of GSK3 signaling in iPSC-derived human neurons. Collectively, he noted, through
the use of genetically accurate cell models and in using iPSC-derived human neurons, these
studies will enable a better understanding of the role of DISC1/GSK3 in regulating signaling
pathways implicated in schizophrenia, as well as potentially lead to the identification of new
targets and improved treatments.
Targeting the PI3K/AKT pathway: novel therapeutic options for schizophrenia
Neuregulin 1 (NRG1) and ErbB4, critical neurodevelopmental genes, are implicated in
genetic risk for schizophrenia, but the biological mechanisms are unknown. Amanda J. Law
(National Institute of Mental Health) presented work testing the hypotheses that aberrant
PI3K/AKT signaling represents a pathogenic consequence of schizophrenia-associated
genetic variation in ErbB4 and that pharmacological manipulation of this pathway may
represent a novel therapeutic avenue for the treatment of psychosis. She explained that her
group has used an “integrative translational neuroscience approach” to test the hypothesis,
incorporating data from patient-derived Iymphoblastoid B cells, human brain mRNA
expression profiling, clinical genetics, and pharmacological studies in rodents. These results
pinpoint a genetically regulated pathway associated with schizophrenia and with ErbB4
genetic risk variation involving upregulation of a Pl3K-linked ErbB4 receptor CYT-l and of
a specific phosphoinositide 3-kinase (PI3K) subunit. Law presented intracellular signaling
data collected in human Iymphoblastoid cells showing that NRG1-mediated phosphatidyl-
inositol,3,4,5-triphosphate [PI(3,4,5)P3] production (and cell migration) is associated with
ErbB4 risk genotype and PI3K enzyme levels and is significantly impaired in patients with
schizophrenia. In the human brain, the association of ErbB4 genotype and PI3K subunit
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expression was confirmed, and antipsychotic drug administration was found to downregulate
expression of the PI3K subunit, implicating the PI3K pathway as a novel therapeutic target.
Specific inhibition of the PI3K subunit using a small molecule inhibitor blocks the effects of
amphetamine in a mouse pharmacological model of psychosis. Law posited that these
studies provide novel insight into how ErbB4 may contribute to the pathophysiology of
schizophrenia, reveal a previously unidentified link between NRG1-ErbB4 and PI3K
signaling in the disorder, and suggest that a specific PI3K merit further consideration as a
molecular target for rationally designed drugs for the treatment of psychiatric disorders.
Evaluation of potent, selective, and peripherally available kynurenine aminotransferase II
inhibitors for the treatment of cognitive deficits in schizophrenia
Representing work conducted in the private sector, Brian Campbell (Pfizer) discussed recent
work on a naturally occurring NMDA agonist, kynurenic acid (KYNA). KYNA is a
biologically active byproduct of tryptophan metabolism that is reported to act as an
endogenous antagonist of NMDA receptors and may also interfere with nicotinic α7
receptor function. Since KYNA levels are elevated in schizophrenic patients, it has been
hypothesized that this may contribute to the cognitive deficits observed in schizophrenia.
Though inhibitors of kynurenine aminotransferase 11 (KAT II), the primary enzyme
involved in brain KYNA synthesis, have been proposed as targets to treat symptom domains
in schizophrenia, research into this hypothesis has been hampered by lack of potent,
selective, and brain penetrant tools. Campbell reported on the discovery and
pharmacological characterization of a new class of KAT II inhibitors with nanomolar
potency, >1000-fold selectivity over other kynurenine pathway enzymes, and excellent brain
penetration. Systemic administration rapidly decreased KYNA by as much as 80% in brain
dialysates in a dose-dependent manner. In addition, Campbell detailed the profiling of these
compounds through a range of animal models relevant for domains of schizophrenia, which
revealed efficacy in models of working memory in both rodents and non-human primates
and also in a rat model of attention (i.e., a sustained attention task). Furthermore, Campbell
and the group at Pfizer have found activity in an anhedonia model (chronic mild stress),
which may suggest therapeutic utility for the negative symptoms of schizophrenia. These
compounds are inactive in classical models of antipsychotic activity, suggesting that KAT II
inhibitors may be suitable as adjunctive agents, given along with antipsychotics, to treat the
cognitive and negative symptoms associated with schizophrenia that are so poorly managed
today.
Genes to function to symptoms
Session chair: John H. Krystal
Large-scale neuronal analysis as a functional endophenotype for schizophrenia
Bita Moghaddam (University of Pittsburgh) opened the final session of the meeting.
Dissatisfied with how simple circuit versions of the glutamate hypothesis of schizophrenia
fail to deliver for the whole brain, she proposed an alternative way of thinking about the
disorder. Instead of seeing the main clues we have for schizophrenia—NMDA receptor
hypofunction and decreased GAD67, an enzyme that synthesizes GABA—as factors that
contribute to the disorder, she suggested that decreased GAD67 may instead reflect a
compensation for abnormal levels of glutamate. If markers of disease like these are
compensatory, rather than primary, then trying to correct them would give opposite effects
than expected. With this in mind, she cited a tightly regulated GABA shunt in mitochondria
that recycles GABA molecules from glutamate. Moghaddam suggested that imbalances in
GABA and glutamate levels could stem from improper mitochondrial function—something
with repercussions for excitatory and inhibitory signaling throughout the brain.
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Translational neuroscience for schizophrenia
Seeking to better simulate the molecular processes underway in neurons in disease, Akira
Sawa (Johns Hopkins University) reported on the “garden of human neural cells” growing in
his lab. He has had some success in maintaining olfactory neurons from humans obtained
through a relatively noninvasive nasal biopsy,15 deriving human neurons from iPSCs,16 and
deriving neurons directly from human skin cells.17 After two weeks of treatment in media,
these latter neurons, called induced neurons (iN), showed neuron-specific markers and fired
action potentials.
As an example of the dividends these approaches may provide, Sawa showed a comparison
of mRNA profiles in olfactory neurons between people with schizophrenia and controls. The
groups differed in genes related to actin binding, the NF-κB protein complex involved in
DNA transcription, intracellular protein transport, and immune and stress responses.
Consistent with these changes, olfactory neurons from patients with schizophrenia show
abnormalities in association with cytoskeletons and oxidative stress (Table 2).
Behavioral selectivity of β-arrestin: dependent signaling of dopamine D2 receptor in the
CNS
The last three speakers discussed whether there might be ways to refine dopamine signaling
in the brain to treat schizophrenia more effectively and with fewer side effects. Starting with
D2Rs, the target of all antipsychotics, Marc Caron (Duke University) noted that D2Rs
engage both a G protein–coupled pathway and one involving the scaffolding protein β-
arrestin-2, which in turn activates the AKT/GSK3β signaling independently associated with
schizophrenia.
To probe how much this β-arrestin-2 pathway mediates psychosis-like behaviors in mice, he
disabled it by removing GSK3β in D2R-containing neurons. This interfered with
apomorphine-induced rearing as well as amphetamine-induced hyperlocomotion and
prepulse inhibition, but not cognitive tasks. Removing GSK3β’s target, β-catenin, from
D1R-containing neurons induced more amphetamine-induced psychosis, whereas removing
it from D2R-containing neurons induced less. Together, the results implicate this pathway in
psychosis-like behaviors and antipsychotic response, and the extent of its contribution may
be further delineated with D2R mutants engineered to selectively signal through either the G
protein or the β-arrestin-2 pathway.
The schizophrenia risk gene CAV1 is both propsychotic and required for antipsychotic
drug activity at 5-HT2A serotonin receptors in vivo
In a later talk (see below), John Allen (University of North Carolina) reported new efforts to
discover D2R ligands that selectively activate the β-arrestin-2 pathway but not the G protein
pathway. In a chemical biology effort in Bryan Roth’s laboratory (University of North
Carolina), the group screened hundreds of new compounds and came up with two that are
biased for their signaling activity at the D2R-β-arrestin-2 pathway. When administered to
mice, these arrestin-biased compounds decreased PCP- or amphetamine-induced
hyperlocomotion without increasing catalepsy. These results suggest that selective D2R-β-
arrestin-2 signaling and recruitment may contribute to antipsychotic activity without motor
side effects.
The dopamine D1-D2 receptor heteromer: novel signaling complex with potential role in
schizophrenia
In another twist for dopamine signaling, Susan George (University of Toronto) presented her
evidence for a novel dopamine receptor made up of a D1R and a D2R. This combination
receptor offers a new mode of signaling for dopamine because it activates a G protein
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pathway that is not induced when either receptor is activated alone. The D1-D2 heteromers
occur endogenously in the brain and are enriched in the nucleus accumbens and globus
pallidus of rats. Using a competitive binding assay to detect a high-affinity state for a D2
agonist in the D1-D2 heteromer, George found this state is enhanced in rats treated with
amphetamine and in the globus pallidus of the postmortem brain in schizophrenia. The work
suggests both that abnormal coupling between D1 and D2 could be a molecular marker for
pathological states in the brain and that this coupling may be a new treatment target—
something that has already been explored in mouse models of depression.
Serotonin signaling is also thought to contribute to schizophrenia symptoms, and the
atypical antipsychotics have been designed to also target 5-HT2A serotonin receptors,
following suggestions that this activity set clozapine apart from the typical antipsychotics.
Prompted by a rare CNV found in the caveolin-1 (CAV1) gene in a case of schizophrenia,18
John Allen explored the state of serotonin signaling in knockout mice missing CAV1. CAV1
encodes a scaffolding protein involved in clustering diverse signaling molecules together,
including 5-HT2A receptors.19 Loss of CAV1 resulted in an increased sensitivity to PCP-
induced hyperlocomotion and disrupted prepulse inhibition, suggesting a propsychotic-like
effect in the mice. Loss of the CAV1 gene also attenuated the activity of atypical
antipsychotics and 5-HT2A antagonists in behavioral studies (Fig. 4). Similarly, these mice
made fewer head twitches in response to a hallucinogenic 5-HT2A agonist and also disrupted
5-HT2A signalingin cortical neurons. The number of 5-HT2A receptors was normal in these
mice, which suggests that loss of the CAV1 scaffold mislocalized 5-HT2A receptors and
their downstream effector molecules, compromising their function and resulting in
compromised antipsychotic activity.20
Although the crowd was dwindling, energy remained high at the end of the talks, with
several people saying that they felt optimistic about the prospects for discovering truly
innovative drugs for schizophrenia. One participant raised the issue of specificity, asking
how disturbances to intracellular signaling pathways available to all cells can produce the
malfunctions in specific brain circuits observed in schizophrenia. Moghaddam suggested
that patterns of metabolic activity, combined with aberrant signaling, somehow target certain
circuits for dysfunction. John Krystal (Yale University) suggested a genetic explanation,
noting that susceptible brain regions in schizophrenia are the most recently evolved and thus
could be the most genetically labile. Either way, a challenge will be to deliver treatment to
ailing brain circuits without disrupting those that are functioning normally.
In his closing remarks, Krystal called the meeting “a next-generation conference” with
research beginning to meet the urgent need for mechanistically novel compounds. “What’s
exciting is not how far we’ve come, but the possibility that we might be getting to the point
where we can use science to guide psychiatry.
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Clozapine but not haloperidol, alone or in combination with VPA, induces reelin promoter
demethylation. Mice were pretreated for seven days with methionine to hypermethylate
reelin and GAD67 promoters. After methionine withdrawal, various doses of clozapine or
haloperidol alone or combined with valproate (VPA) (0.7 mg/kg/sc) were administered
twice a day for three days. Open circles denote mice that did not receive VPA. Filled circles
denote mice that received VPA. The data represent the mean ± SE of three mice. P < 0.05
when VEH + VPA-treated mice were compared with VEH-treated mice; P < 0.05 when
VEH + clozapine-treated mice were compared to VEH-treated mice; and P < 0.02 when
VEH + VPA-treated mice were compared with clozapine + VPA-treated mice.7
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Cell type–specific epigenome mapping in human brain. Left: schematic presentation of the
nucleosome as the elementary unit of chromatin, composed of a histone octamer (blue)
around which 146 bp of DNA (black) is wrapped. Histones and the genomic DNA are
subject to various types of covalent modifications. Right: flow chart starting with extraction
of nuclei from postmortem brain tissue for subsequent immunotagging with neuron nuclei–
specific marker (NeuN), fluorescence-activated separation and sorting of neuronal and
nonneuronal nuclei, and preparation of chromatin with enzyme-based digestion
(micrococcal nuclease, MNase) into mononucleosomes. This is followed by
immunoprecipitation with site- and modification-specific antihistone antibody (for example,
antitrimethyl-histone H3-lysine 4) and massively parallel sequencing. Sequence tags from
the immunoprecipitates (ChIP-seq) are then uploaded into the genome browser in order to
visualize histone metylation landscapes at selected loci, as shown here for the GAD1/
GAD67 promoter.
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DISC1/GSK3 signaling involved in regulating neuroplasticity and its regulation. While
lithium inhibits GSK3 both indirectly and directly, CHIR-99021 is an ATP competitive
inhibitor of GSK3 that mimics the cellular and behavioral effects of lithium. AKTI-17 is an
allosteric inhibitor of AKT that blocks the ability of lithium to modulate TCF/LEF–mediated
transcription and behavior but not the effect of CHIR-99021.
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Genetic deletion of schizophrenia risk gene caveolin-1 in mice annenuates antipsychotic
drug activity. (A) Littermate wildtype (WT) and caveolin-1 knockout (Cav-1 KO) mice were
injected with vehicle, 0.5, or 1.0 mg/kg clozapine (CLOZ) and were followed 30 min later
by 6 mg/kg phencyclidine (PCP) and immediately placed into acoustic startle response
chambers. Clozapine-normalized PCP-disrupted prepulse inhibition (PPI) in WT but not in
Cav-1 KO mice at the 4 dB and 8 dB prepulse levels (mean ± SEM, n = 12 littermate pairs;
*, P < 0.05 versus WT Saline or Cav-1 KO Saline at each prepulse level). (B) Littermate
WT and Cav-1 KO mice received vehicle or 1.0 mg/kg CLOZ and were placed into open
field locomotion chambers and allowed to acclimate; 30 min later, mice were injected with
PCP and the total distance traveled (cm) was determined. Clozapine was less effective at
suppressing hyperlocomotion in Cav-1 KO mice (mean ± SEM, n = 12 littermate pairs).20
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Table 1
Genetic characteristic of SCZ
SCZ is highly polygenic
• Highly significant, replicated, neg control
• Withstood attempts at falsification
• (New) Not due to pop stratification
• Accounts for one-third of variance in liability to SCZ (two methods), half heritability
• Genetic overlap between SCZ and BIP
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Table 2
Translational neuroscience approaches to schizophrenia
Advantage Disadvantage
Olfactory neurons • Live immature neuron-like cells
• Sufficiently homogeneous
• In vitro functional study
• Easy for preparation
• May not completely represent brain
• May not be able to chase several
developmental phases
iPS cells—derived neurons • Live neurons
• In vitro functional study
• May be able to differentiate into many
lineages, several developmental stages
• Laborious, high cost
• Heterogeneity
• Reprogramming artifacts
iN cells (induced neuronal
cells)
• Live neurons
• In vitro functional study
• Potentially high-throughput
• Differentiation into many lineages has not
yet been fully established
Autopsied brains • Brain tissue • Many confounding factors
• Functional assay not available
• Less of a link to developmental process
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